Antimicrobial Guanidinylate Polycarbonates Show Oral in Vivo Efficacy Against Clostridioides Difficile
Menglin Xue,Soumyadeep Chakraborty,Ruixuan Gao,Shaohui Wang,Meng Gu,Ning Shen,Lulu Wei,Chuanhai Cao,Xingmin Sun,Jianfeng Cai
DOI: https://doi.org/10.1002/adhm.202303295
IF: 10
2024-02-08
Advanced Healthcare Materials
Abstract:The emerging antibiotic resistance has been named by the World Health Organization (WHO) as one of the top 10 threats to public health. Notably, methicillin‐resistant Staphylococcus aureus (MRSA) and vancomycin‐resistant Enterococcus faecalis (VREF) are designated as serious threats, whereas Clostridioides difficile (C. difficile) is recognized as one of the most urgent threats to human health and unmet medical need. Among different strategies to combat these bacteria, host‐defense peptide (HDP) – mimicking polymer materials are found to be versatile and promising. However, the vast majority of antibiotic polymer applications were limited to topical application due to their potential systematic toxicity. Herein, we report the design and application of novel biodegradable polymers – the lipidated antimicrobial guanidinylate polycarbonates. These polymers showed potent antimicrobial activity against a panel of Gram‐negative and Gram‐positive bacteria with fast‐killing kinetics and low resistance development tendency. The mechanism of the bacterial killing process was investigated, which suggested that the antimicrobial activity of the polymer was mainly due to bacterial membrane disruption, analogous to that of HDPs. More importantly, the optimal polymer showed excellent antibacterial activity against C. difficile infection (CDI) in vivo via oral administration, which is very unusual as polymer applications are generally limited to injection. In addition, compared with vancomycin, the standard drug for the treatment of CDI but suffers from short protective efficacy and a high relapse rate, the polymer demonstrated a much‐prolonged therapeutic effect and virtually diminished recurrence rate of CDI. The convenient synthesis, easy scale‐up, low cost, as well as biodegradability of this class of polycarbonates, together with their in vitro broad‐spectrum antimicrobial activity and orally in vivo efficacy against CDI, suggest the great potential of lipidated guandinylate polycarbonates as a new class of antibacterial biomaterials to treat CDI and combat emerging antibiotic resistance. This article is protected by copyright. All rights reserved
nanoscience & nanotechnology,engineering, biomedical,materials science, biomaterials